Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @FiercePharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FiercePharma
-
Novo extends China employees' holiday amid coronavirus threat; expects manufacturing to start up next weekhttps://www.fiercepharma.com/pharma/novo-extends-employees-holiday-by-one-week-amid-coronavirus-threat …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up https://www.fiercepharma.com/pharma/biogen-wins-tecfidera-patent-challenge-from-mylan-sending-shares-way-up …
$BIIB$MYLHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
GlaxoSmithKline's spinoff plan is here—and it may not be limited to consumer healthhttps://www.fiercepharma.com/pharma/gsk-kicks-off-2-year-program-to-spin-off-consumer-health-and-possibly-prescription …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Federal prosecutors snare 3rd generics exec in price-fixing investigationhttps://www.fiercepharma.com/pharma/federal-prosecutors-snare-3rd-generics-exec-price-fixing-investigation …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead CEO O'Day feels 'sense of urgency' on dealmaking as Kite writedowns add uphttps://www.fiercepharma.com/pharma/gilead-s-kite-write-downs-add-up-as-company-feels-sense-urgency-for-m-a …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novo's next-gen GLP-1 Ozempic smashes blockbuster barrier amid ramp-up for Rybelsus rollouthttps://www.fiercepharma.com/pharma/as-novo-nordisk-gears-up-for-its-big-rybelsus-launch-ozempic-carried-torch-2019 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Merck preaches the value of ‘focus’ as it spins off $6.5B women’s health, biosimilars unitshttps://www.fiercepharma.com/pharma/merck-preaches-value-focus-as-it-spins-off-6-5b-women-s-health-biosimilars-units …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Copycats hurt Amgen in 2019. Can Otezla, new launches ease the pain?https://www.fiercepharma.com/pharma/copycats-weighed-amgen-2019-but-company-says-new-launches-biosims-and-otezla-will-drive …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ocrevus, Hemlibra offset Roche's biosim loss. But what about those lackluster Xofluza sales?https://www.fiercepharma.com/pharma/ocrevus-hemlibra-offset-roche-s-biosim-loss-but-what-about-those-lackluster-xofluza-sales …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alexion to its detractors: Take a look at our Soliris switching and budding pipelinehttps://www.fiercepharma.com/pharma/alexion-to-its-detractors-take-a-look-at-our-soliris-switching-and-robust-pipeline …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulinhttps://www.fiercepharma.com/pharma/novartis-sandoz-loses-bid-to-break-united-therapeutics-device-deal-for-remodulin …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Aurobindo receives tough news about FDA inspectionhttps://www.fiercepharma.com/manufacturing/fda-tells-aurobindo-it-found-significant-issues-at-plant …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biogen’s Tecfidera holds its own in MS as competitive and generic threats loomhttps://www.fiercepharma.com/pharma/biogen-s-tecfidera-holds-its-own-ms-as-competitive-and-generic-threats-loom …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bayer’s Nubeqa scores key prostate cancer win in battle with Pfizer, J&Jhttps://www.fiercepharma.com/marketing/bayer-s-nubeqa-gets-better-chance-at-challenging-pfizer-and-j-j-prostate-cancer-key …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lilly gears up for 'top-tier' growth to 2025 thanks to its new launcheshttps://www.fiercepharma.com/pharma/lilly-gears-up-for-top-tier-growth-to-2025-thanks-to-its-new-launches …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?https://www.fiercepharma.com/pharma/teva-s-ajovy-finally-gets-autoinjector-nod-can-it-close-gap-amgen-lilly-meds …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novartis calls it quits on Advair generic—and takes a $442M hithttps://www.fiercepharma.com/pharma/after-years-development-and-fda-rejection-novartis-calls-it-quits-advair-generic-and-takes …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Purdue was unnamed opioid maker at center of EHR kickback scheme: reporthttps://www.fiercepharma.com/pharma/purdue-was-unnamed-opioid-maker-at-center-healthcare-kickback-scheme-report …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Incyte doubles down on atopic dermatitis push with trial win for ruxolitinib creamhttps://www.fiercepharma.com/pharma/incyte-doubles-down-atopic-dermatitis-push-trial-win-for-jak-med-jakafi …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
WuXi Biologics says coronavirus will not halt flow of critical drugshttps://www.fiercepharma.com/manufacturing/wuxi-biologics-says-coronavirus-will-not-halt-flow-critical-drugs …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.